Cost and effectiveness analysis on different schemes in the treatment of mycoplasma pneumonia complicated with bacterial infection

LAN Xuerong; HUANG Xuemin; LIU Zhifang; ZENG Guangfan

doi:10.3969/j.issn.1006-0111.2017.04.022

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To evaluate the cost and effectiveness for five combination therapy of β-lactam antibiotic with azithromycin in the treatment of mycoplasma pneumonia (MP) complicated with bacterial infection. Methods A retrospective study was conducted to compare the cost and effectiveness of the five regimens. Results The effective rates of group A, B, C, D and E were 97.29%, 100%, 96.55%, 95.65% and 97.36% respectively. The costs were (2 831.13±910.16) yuan,(2 816.31±127.11) yuan,(3 453.29±645.89) yuan,(4 382.42±1484.26) yuan,(3 703.39±124.86) yuan respectively. The cost-effectiveness ratios were (29.10±9.36), (28.16±5.24), (35.77±6.69), (38.04±7.90)and (35.26±10.10)respectively. Conclusion In terms of pharmacoeconomics, the combination of cefpiramide with azithromycin in group B has the lowest cost and cost-effectiveness ratio. This regimen is the most effective and economically favored combination. It is the treatment of first choice for pediatric MP patients complicated with bacterial infection.

Cost and effectiveness analysis on different schemes in the treatment of mycoplasma pneumonia complicated with bacterial infection

Heyuan Maternal and Children Health Care Hospital of Guangdong Province, Heyuan 517000, China

Received Date: 2016-11-21

Rev Recd Date: 2017-03-20

Key words:

Abstract: Objective To evaluate the cost and effectiveness for five combination therapy of β-lactam antibiotic with azithromycin in the treatment of mycoplasma pneumonia (MP) complicated with bacterial infection. Methods A retrospective study was conducted to compare the cost and effectiveness of the five regimens. Results The effective rates of group A, B, C, D and E were 97.29%, 100%, 96.55%, 95.65% and 97.36% respectively. The costs were (2 831.13±910.16) yuan,(2 816.31±127.11) yuan,(3 453.29±645.89) yuan,(4 382.42±1484.26) yuan,(3 703.39±124.86) yuan respectively. The cost-effectiveness ratios were (29.10±9.36), (28.16±5.24), (35.77±6.69), (38.04±7.90)and (35.26±10.10)respectively. Conclusion In terms of pharmacoeconomics, the combination of cefpiramide with azithromycin in group B has the lowest cost and cost-effectiveness ratio. This regimen is the most effective and economically favored combination. It is the treatment of first choice for pediatric MP patients complicated with bacterial infection.

HTML

Reference (9)

[1]	王晓红, 王岱明. 注射用阿奇霉素治疗儿童肺炎的临床疗效及安全性[J].中国新药杂志, 2001, 10(9): 695-696.
[2]	柯莉芹, 王凤美, 李银洁, 等. 儿童肺炎支原体肺炎流行病学特征[J].中国当代儿科杂志, 2013, 15(1): 33-36.
[3]	谢振伟,臧彦楠,王晓玲, 等. 四种方案治疗支原体肺炎合并细菌感染的药物经济学评价[J].中国医院药学杂志, 2015,35(23): 2139-2142.
[4]	陆权, 李昌崇.再论儿童社区获得性肺炎[J]. 中华儿科杂志,2013,51(10): 721-723.
[5]	张琳.支原体肺炎发病机制及临床分析[J].第一军医大学学报, 2005, 25(12):1574-1576.
[6]	中华医学会儿科学分会呼吸学组,《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识 (2015 年版)[J]. 中华实用儿科临床杂志, 2015, 30(17): 1304-1308.
[7]	李红.红霉素联合阿奇霉素治疗小儿支原体肺炎疗效观察[J]. 临床合理用药杂志,2013,6(26): 75-76.
[8]	吴玉洲, 韦冠, 陈永法. 儿科领域的药物经济学研究现状初探——基于美国《药物经济学》杂志[J].中国药物经济学, 2013, 8(2): 12-15.
[9]	胡春阳,韩晟,陈路佳,等.他氟前列素与拉坦前列素治疗原发性开角型青光眼的成本效果分析[J].中国新药杂志,2013,22(23): 2831-2836.

Message Board

Cost and effectiveness analysis on different schemes in the treatment of mycoplasma pneumonia complicated with bacterial infection

doi: 10.3969/j.issn.1006-0111.2017.04.022

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views